Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alexander Perl, MD
Hospital of the University of Pennsylvania - Philadelphia, PA
Principal Investigator - Catherine Smith, MD
University of California Medical Center - San Francisco, CA
Principal Investigator - Gail Roboz, MD
Weill Cornell Medical College/New York Presbyterian Hospital - New York, NY
Principal InvestigatorKOL profile → - John Pagel, MD, PhD
Fred Hutchinson Cancer Research Center - Seattle, WA
Principal Investigator - Mark Levis, MD, PhD
Johns Hopkins University
Principal Investigator - Olga Frankfurt, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago, IL
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsf Helen Diller Family Family Comprehensive Cancer Center
San Francisco, California, United States
- Northwestern University
Chicago, Illinois, United States
- Johns Hopkins University
Baltimore, Maryland, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- New York Presby Hospital, Weill Medical College at Cornell University
New York, New York, United States
- University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
- Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Nov 2011
- Primary completion
- 20 Jan 2015
- Completion
- 9 Jan 2018
- Last update posted
- 2 Mar 2020
- Registered enrollment
- 90
- Registry id
- NCT01349049
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.